Title: Phosphodiesterase 5 (PDE-5) inhibitors (sildenafil, tadalafil, and vardenafil) effects on
esophageal motility: a systematic review
Version: 3 Date: 18 Dec 2022
Reviewer's report:
Phosphodiesterase 5 (PDE 5) inhibitors (sildenafil, tadalafil, and vardenafil) in patients with
esophageal motility disorders: a systematic literature review
The authors have done review of the literature on PDE5 inhibitors in various motility disorders.
This is a gray area and rightly so needs evidence.
The study is good but needs better framing for a meaningful paper for readers.
Lower esophageal tone and contraction wave amplitude were reported to be decreased after
using PDE5 inhibitors in how many studies?
What were the main outcomes of the study? Enumerate in methods
How was the quality assessment done for the included studies? This has to be mentioned in
methods and the outcomes of assessment in results.
If there were a good number of trials, can the case reports be excluded or compiled in a separate
table? Better to focus on the outcomes of clinical trials.
In PRISMA, there are 3 studies from other sources. How were these three additional studies
obtained ?
Could you summarize your results according to the diseases?
The adverse events profile and drug discontinuation results should be summarized separately
in results
Discussion needs to focus on limitations of drug therapy in motility disorders, manometric
alteration produced by PDE5 inhibitors and various mechanisms of PDE5 inhibitors. What are
the conditions where PDE5 inhibitors could be started and where it lacks evidence?
Title: Phosphodiesterase 5 (PDE-5) inhibitors (sildenafil, tadalafil, and vardenafil) effects on
esophageal motility: a systematic review
Version: 3 Date: 18 Dec 2022
Reviewer's report:
Phosphodiesterase 5 (PDE 5) inhibitors (sildenafil, tadalafil, and vardenafil) in patients with
esophageal motility disorders: a systematic literature review
The authors have done review of the literature on PDE5 inhibitors in various motility disorders.
This is a gray area and rightly so needs evidence.
The study is good but needs better framing for a meaningful paper for readers.
Lower esophageal tone and contraction wave amplitude were reported to be decreased after
using PDE5 inhibitors in how many studies?
What were the main outcomes of the study? Enumerate in methods
How was the quality assessment done for the included studies? This has to be mentioned in
methods and the outcomes of assessment in results.
If there were a good number of trials, can the case reports be excluded or compiled in a separate
table? Better to focus on the outcomes of clinical trials.
In PRISMA, there are 3 studies from other sources. How were these three additional studies
obtained ?
Could you summarize your results according to the diseases?
The adverse events profile and drug discontinuation results should be summarized separately
in results
Discussion needs to focus on limitations of drug therapy in motility disorders, manometric
alteration produced by PDE5 inhibitors and various mechanisms of PDE5 inhibitors. What are
the conditions where PDE5 inhibitors could be started and where it lacks evidence?
Please review this paper.
user
Title: Phosphodiesterase 5 (PDE-5) inhibitors (sildenafil, tadalafil, and vardenafil) effects on
esophageal motility: a systematic review
Version: 3 Date: 18 Dec 2022
Reviewer's report:
Phosphodiesterase 5 (PDE 5) inhibitors (sildenafil, tadalafil, and vardenafil) in patients with
esophageal motility disorders: a systematic literature review
The authors have done review of the literature on PDE5 inhibitors in various motility disorders.
This is a gray area and rightly so needs evidence.
The study is good but needs better framing for a meaningful paper for readers.
Lower esophageal tone and contraction wave amplitude were reported to be decreased after
using PDE5 inhibitors in how many studies?
What were the main outcomes of the study? Enumerate in methods
How was the quality assessment done for the included studies? This has to be mentioned in
methods and the outcomes of assessment in results.
If there were a good number of trials, can the case reports be excluded or compiled in a separate
table? Better to focus on the outcomes of clinical trials.
In PRISMA, there are 3 studies from other sources. How were these three additional studies
obtained ?
Could you summarize your results according to the diseases?
The adverse events profile and drug discontinuation results should be summarized separately
in results
Discussion needs to focus on limitations of drug therapy in motility disorders, manometric
alteration produced by PDE5 inhibitors and various mechanisms of PDE5 inhibitors. What are
the conditions where PDE5 inhibitors could be started and where it lacks evidence?
assistant